HLF vs NAGE
HLF: Global direct-selling nutrition company with 46 years of history selling weight management, protein, and wellness products through an independent distributor network in 95 markets worldwide. NAGE: A global bioscience company commercializing nicotinamide riboside (Niagen®), a NAD+ precursor, through consumer supplements, pharmaceutical-grade ingredient supply, and clinical research collaborations targeting healthy aging.
Side-by-side fundamentals
| Metric | HLF | NAGE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $12.19 | $3.40 | |
| Market cap as of 2026-07-23 | $1.3B | $270M | |
| P/E as of 2026-07-23 | 5.26 | 14.49 | HLF lower |
| PEG as of 2026-07-23 | n/a | 0.61 | |
| Net margin as of 2026-07-23 | +4.7% | +14.3% | NAGE higher |
| Gross margin as of 2026-07-23 | +77.8% | +64.3% | HLF higher |
| Operating margin as of 2026-07-23 | -14.2% | +13.7% | NAGE higher |
| ROE as of 2026-07-23 | +170.7% | +25.4% | HLF higher |
| ROA as of 2026-07-23 | +8.6% | +18.2% | NAGE higher |
| Debt / equity as of 2026-07-23 | 10.41 | 0.00 | NAGE lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.7% | +20.8% | NAGE higher |
| Revenue CAGR (3y) SEC XBRL | -1.1% | +21.6% | NAGE higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 0.90 | 2.12 | |
| 1-year return as of 2026-07-22 close | +30.4% | -64.1% | HLF higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.